CaaMTech logo

CaaMTech

caam.tech

CaaMTech is a pharmaceutical drug discovery company that creates and optimizes small-molecule, psychedelic-inspired therapeutics, including novel tryptamines, for mental health conditions. It studies how chemical structure relates to biological activity and screens compounds for safety and efficacy, aiming to develop medicines with desired effects and fewer unwanted side effects.

Facts

HQ
Issaquah, WA, US
Sectors
Pharmaceutical Manufacturing
Founded
2019
Employees
7

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about CaaMTech

See all 2

Seattle-area CaaMTech Raises $22M to Develop Novel Tryptamines, Aiming for Human Testing

Seattle-area startup CaaMTech raised $22 million to develop synthesized tryptamine compounds similar to those in psilocybin and LSD, aiming to create defined formulations that maximize desired psychedelic effects and minimize side effects. The company says many of its novel agents are unscheduled in the U.S., and it plans to advance toward human testing amid growing investment and interest in psychedelics for mental-health treatments.

People

  • Andrew Chadeayne Founder & CEO
  • Davis Wuolle Executive, Chief Technology Officer & Chief Marketing Officer

Online

Questions about CaaMTech

What is CaaMTech?

caam.tech

Who are the people behind CaaMTech?

Seattle Flow lists Andrew Chadeayne (Founder & CEO) and Davis Wuolle (Executive, Chief Technology Officer & Chief Marketing Officer) at CaaMTech.

Who invested in CaaMTech, and how much has it raised?

Members of Seattle Flow see CaaMTech's funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is CaaMTech based?

CaaMTech is headquartered in Issaquah, WA, US.

When was CaaMTech founded?

CaaMTech was founded in 2019.

How many people work at CaaMTech?

CaaMTech has 7 employees.